Combining clinical parameters, patient’s individual characteristics, and circulating cytokine levels, especially IL-6 and TGF-β1, in prediction models might be useful for the prediction of adverse normal tissue reactions to radiotherapy in patients with prostate cancer. Here, TGFB1 is linked to prostate carcinoma.